Tadalafil Mylan

tadalafil

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Tadalafil Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Tadalafil Mylan.

For practical information about using Tadalafil Mylan, patients should read the package leaflet or contact their doctor or pharmacist.

: Tadalafil Mylan is used to treat men with erectile dysfunction (sometimes called impotence) when they cannot get, or keep, a hard penis (erection) sufficient for satisfactory sexual activity. For Tadalafil Mylan to be effective in this condition, sexual stimulation is required.
Tadalafil Mylan can also be used in men to treat the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous), which involve problems with the flow of urine.
Tadalafil Mylan contains the active substance tadalafil. It is a ‘generic medicine’. This means that Tadalafil Mylan is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Cialis.

: For treating erectile dysfunction, the recommended dose of Tadalafil Mylan is 10 mg taken ‘on demand’ at least 30 minutes before sexual activity. The dose may be increased to 20 mg for men who do not respond to the 10 mg dose. The maximum recommended dosing frequency is once per day, but continuous daily use of 10 or 20 mg Tadalafil Mylan is not recommended. Tadalafil Mylan can be used at a lower dose once a day in men who intend to use it frequently (twice a week or more), based on the doctor’s judgment. The dose is 5 mg once a day, but can be lowered to 2.5 mg once a day depending on how well it is tolerated. The medicine should be taken around the same time every day and the appropriateness of the once-a-day dosing should be re-assessed regularly.
For treating men with benign prostatic hyperplasia, or men with both benign prostatic hyperplasia and erectile dysfunction, the recommended dose is 5 mg once a day.
Patients with severely impaired liver or kidney function should not take more than 10 mg in one dose. Once-a-day dosing is not recommended in patients with severely impaired kidney function, and should only be prescribed to patients with impaired liver function after a careful evaluation of the benefits and risks of taking the medicine.
Tadalafil Mylan can only be obtained with a prescription.

: The active substance of Tadalafil Mylan, tadalafil, belongs to a group of medicines called 'phosphodiesterase type-5 (PDE5) inhibitors'. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax, allowing the flow of blood into the corpora, producing the erection. Men with erectile dysfunction do not have enough cGMP to produce or maintain an erection. By blocking the breakdown of cGMP, Tadalafil Mylan restores erectile function. However, sexual stimulation is still needed. By blocking the phosphodiesterase enzyme and preventing the breakdown of cGMP, Tadalafil Mylan also improves the blood flow to, and relaxes the muscles of, the prostate and bladder. This may reduce the problems with the flow of urine which are symptoms of benign prostatic hyperplasia

: Because Tadalafil Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Cialis. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

: Because Tadalafil Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

: The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Tadalafil Mylan has been shown to have comparable quality and to be bioequivalent to Cialis. Therefore, the CHMP’s view was that, as for Cialis, the benefit outweighs the identified risk. The Committee recommended that Tadalafil Mylan be approved for use in the EU.

: A risk management plan has been developed to ensure that Tadalafil Mylan is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tadalafil Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.
Further information can be found in the summary of the risk management plan .

: The European Commission granted a marketing authorisation valid throughout the European Union for Tadalafil Mylan on 21 November 2014.
For more information about treatment with Tadalafil Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

List item

Tadalafil Mylan : EPAR - Summary for the public (PDF/92.82 KB)

First published: 19/12/2014
Last updated: 19/12/2014
- Bulgarian
  (PDF/120.25 KB)
- Croatian
  (PDF/114.17 KB)
- Czech
  (PDF/119.34 KB)
- Danish
  (PDF/93.02 KB)
- Dutch
  (PDF/76.48 KB)
- Estonian
  (PDF/92.2 KB)
- Finnish
  (PDF/92.09 KB)
- French
  (PDF/94.01 KB)
- German
  (PDF/95.17 KB)
- Greek
  (PDF/121.67 KB)
- Hungarian
  (PDF/114.29 KB)
- Italian
  (PDF/92.79 KB)
- Latvian
  (PDF/115.23 KB)
- Lithuanian
  (PDF/116.75 KB)
- Maltese
  (PDF/118.56 KB)
- Polish
  (PDF/116.55 KB)
- Portuguese
  (PDF/93.23 KB)
- Romanian
  (PDF/116.5 KB)
- Slovak
  (PDF/117.17 KB)
- Slovenian
  (PDF/114 KB)
- Spanish
  (PDF/93.19 KB)
- Swedish
  (PDF/92.11 KB)
List item

Tadalafil Mylan : EPAR - Risk-management-plan summary (PDF/45.33 KB)

First published: 19/12/2014
Last updated: 19/12/2014

More detail is available in the summary of product characteristics

This EPAR was last updated on 17/01/2020

Authorisation details

Product details
Name	Tadalafil Mylan
Agency product number	EMEA/H/C/003787
Active substance	tadalafil
International non-proprietary name (INN) or common name	tadalafil
Therapeutic area (MeSH)	Erectile Dysfunction
Anatomical therapeutic chemical (ATC) code	G04BE08
Generic	This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder	Mylan S.A.S.
Revision	11
Date of issue of marketing authorisation valid throughout the European Union	21/11/2014
Contact address	117 Allée des Parcs 69800 Saint Priest France

Product information

11/12/2019 Tadalafil Mylan - EMEA/H/C/003787 - IAIN/0017

List item

Tadalafil Mylan : EPAR - Product Information (PDF/568.97 KB)

First published: 19/12/2014
Last updated: 17/01/2020
- Bulgarian
  (PDF/738.57 KB)
- Croatian
  (PDF/712.18 KB)
- Czech
  (PDF/732 KB)
- Danish
  (PDF/602.02 KB)
- Dutch
  (PDF/607.91 KB)
- Estonian
  (PDF/559.62 KB)
- Finnish
  (PDF/572.09 KB)
- French
  (PDF/1001.15 KB)
- German
  (PDF/616.22 KB)
- Greek
  (PDF/788.23 KB)
- Hungarian
  (PDF/563.26 KB)
- Icelandic
  (PDF/543.56 KB)
- Italian
  (PDF/667.65 KB)
- Latvian
  (PDF/696.08 KB)
- Lithuanian
  (PDF/720.46 KB)
- Maltese
  (PDF/773.93 KB)
- Norwegian
  (PDF/557.9 KB)
- Polish
  (PDF/800.49 KB)
- Portuguese
  (PDF/587.01 KB)
- Romanian
  (PDF/758.08 KB)
- Slovak
  (PDF/700.93 KB)
- Slovenian
  (PDF/1.19 MB)
- Spanish
  (PDF/1.21 MB)
- Swedish
  (PDF/585.68 KB)

Annex I - Summary of product characteristics
Annex IIA - Manufacturing-authorisation holder responsible for batch release
Annex IIB - Conditions of the marketing authorisation
Annex IIIA - Labelling
Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

List item

Tadalafil Mylan : EPAR - All Authorised presentations (PDF/32.28 KB)

First published: 19/12/2014
Last updated: 30/03/2017
- Bulgarian
  (PDF/28.5 KB)
- Croatian
  (PDF/26.14 KB)
- Czech
  (PDF/32.45 KB)
- Danish
  (PDF/32.63 KB)
- Dutch
  (PDF/31.69 KB)
- Estonian
  (PDF/33.03 KB)
- Finnish
  (PDF/25.99 KB)
- French
  (PDF/26.46 KB)
- German
  (PDF/26.13 KB)
- Greek
  (PDF/35.41 KB)
- Hungarian
  (PDF/27.62 KB)
- Icelandic
  (PDF/26.03 KB)
- Italian
  (PDF/26.11 KB)
- Latvian
  (PDF/31.98 KB)
- Lithuanian
  (PDF/32.02 KB)
- Maltese
  (PDF/32.41 KB)
- Norwegian
  (PDF/27.17 KB)
- Polish
  (PDF/27.5 KB)
- Portuguese
  (PDF/32.03 KB)
- Romanian
  (PDF/26.36 KB)
- Slovak
  (PDF/27.14 KB)
- Slovenian
  (PDF/28.33 KB)
- Spanish
  (PDF/33.76 KB)
- Swedish
  (PDF/25.91 KB)

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of erectile dysfunction in adult males. In order for tadalafil to be effective, sexual stimulation is required.

Tadalafil Mylan is not indicated for use by women.

Assessment history

Changes since initial authorisation of medicine

List item

Tadalafil Mylan : EPAR - Procedural steps taken and scientific information after authorisation (PDF/167.81 KB)

First published: 27/01/2016
Last updated: 17/01/2020
List item

Tadalafil Mylan-H-A31-1450-C-003787-0005 : EPAR - Assessment Report - Article 31 (PDF/224.68 KB)

Adopted

First published: 10/07/2017
Last updated: 10/07/2017
EMA/420215/2017
List item

Tadalafil Mylan : EPAR - Scientific Conclusion (PDF/36.59 KB)

First published: 10/07/2017
Last updated: 10/07/2017
- Bulgarian
  (PDF/72.03 KB)
- Croatian
  (PDF/63.02 KB)
- Czech
  (PDF/65.68 KB)
- Danish
  (PDF/34.18 KB)
- Dutch
  (PDF/34.86 KB)
- Estonian
  (PDF/33.44 KB)
- Finnish
  (PDF/34.36 KB)
- French
  (PDF/36.62 KB)
- German
  (PDF/38.05 KB)
- Greek
  (PDF/74.19 KB)
- Hungarian
  (PDF/58.22 KB)
- Italian
  (PDF/34.57 KB)
- Latvian
  (PDF/65.46 KB)
- Lithuanian
  (PDF/68.13 KB)
- Maltese
  (PDF/72.95 KB)
- Polish
  (PDF/57.59 KB)
- Portuguese
  (PDF/36.48 KB)
- Romanian
  (PDF/66.66 KB)
- Slovak
  (PDF/56.9 KB)
- Slovenian
  (PDF/61.67 KB)
- Spanish
  (PDF/35.62 KB)
- Swedish
  (PDF/35.56 KB)

Initial marketing-authorisation documents

News

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 September 2014

26/09/2014

Tadalafil Mylan

Table of contents

Overview

Tadalafil Mylan : EPAR - Summary for the public (PDF/92.82 KB)

Tadalafil Mylan : EPAR - Risk-management-plan summary (PDF/45.33 KB)

Authorisation details

Product information

Tadalafil Mylan : EPAR - Product Information (PDF/568.97 KB)

Contents

Tadalafil Mylan : EPAR - All Authorised presentations (PDF/32.28 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Tadalafil Mylan : EPAR - Procedural steps taken and scientific information after authorisation (PDF/167.81 KB)

Tadalafil Mylan-H-A31-1450-C-003787-0005 : EPAR - Assessment Report - Article 31 (PDF/224.68 KB)

Tadalafil Mylan : EPAR - Scientific Conclusion (PDF/36.59 KB)

Initial marketing-authorisation documents

Tadalafil Mylan : EPAR - Public assessment report (PDF/608.74 KB)

CHMP summary of positive opinion for Tadalafil Mylan (PDF/80.05 KB)

News

Related content

More information on Tadalafil Mylan

Questions and answers on generic medicines (PDF/66.45 KB)

How useful was this page?